Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant palbociclib plus HER2-targeted therapy in HER2-positive and ER-positive breast cancer
2014-001984-11Phase 2Completed
- Sponsor
- Michelangelo Foundation
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in breast cancer, sponsored by Michelangelo Foundation. Primary endpoint: Change in Ki67 score from baseline. Started Oct 2014; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-001984-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001984-11.